Definition and research guide
This page combines a MeSH definition, publication statistics and selected research abstracts. It is a starting point for reading the literature, not a medical textbook or a systematic evidence review.
Content available: 4 complete abstracts (865 words), 10 references. Full article text is not stored or reproduced here; follow the PMID, DOI or PMC links to read the original sources and their access terms.
Definition
A specific blocker of dopamine receptors. It speeds gastrointestinal peristalsis, causes prolactin release, and is used as antiemetic and tool in the study of dopaminergic mechanisms.
Definition: NLM Medical Subject Headings (MeSH) scope note (Public domain (U.S. National Library of Medicine); attribution requested). View the MeSH record.
Also known as: Domperidon; Motilium; Domperidone Monohydrochloride; Monohydrochloride, Domperidone; Domperidone Maleate (1:1); Domperidone Maleate; Maleate, Domperidone; R-33,812.
Where it fits in the MeSH classification
- Broader topics
- Piperidines; Benzimidazoles
Research landscape
PubMed indexes 1,962 records tagged with the MeSH heading “Domperidone” (counts retrieved 2026-10-31). 176 of them (9.0%) were published from 2020 onward, and the busiest period so far is through 1999 with 1,133 records.
Reviews account for 145 records (7.4%) and meta-analyses for 26. Randomized controlled trials number 188 (9.6%) as a share of all records on the topic. Randomized trials make up a comparatively large share of this literature, which means many treatment questions have been tested directly.
Show the data
| Period | Records |
|---|---|
| through 1999 | 1,133 |
| 2000-2009 | 278 |
| 2010-2019 | 375 |
| 2020 onward | 176 |
Publication-type chart data
| Type | Records | Share |
|---|---|---|
| Reviews | 145 | 7.4% |
| Meta-analyses | 26 | 1.3% |
| Randomized controlled trials | 188 | 9.6% |
Method: PubMed query "Domperidone"[MeSH Terms] with publication-type and date filters, retrieved 2026-10-31.
Reading the evidence in drugs and chemicals
Studies of a chemical or drug can answer very different questions: what it is and how it behaves in cells and animals, how the body handles it, and whether it changes outcomes in people. Laboratory and animal findings often do not carry over to patients, and observational studies of exposures are confounded by who uses a substance and why. Nothing on this page is a recommendation to use, avoid, start or stop any substance or medicine; talk to a qualified clinician or pharmacist about your own situation. Check the dose, the species, the comparison group and whether a patient-relevant outcome was measured.
Evidence from open-access studies
These open-access studies come from PubMed’s best-match results for this heading (papers whose main topic it is), ranked here by citation count, with one recent addition. Each abstract is reproduced in full under its recorded open licence so that you can read the authors’ own words. They illustrate the literature; they are not a systematic summary of it. Citation counts measure attention, not reliability or clinical benefit.
Fused Deposition Modeling (FDM) 3D Printed Tablets for Intragastric Floating Delivery of Domperidone [1]
Abstract reading summary — source excerpts
- Opening excerpt
- The aim of this study was to explore the feasibility of fused deposition modeling (FDM) 3D printing to prepare intragastric floating sustained release (FSR) tablets.
- Closing excerpt
- All the results showed that FDM based 3D printing might be a promising way to fabricate hollow tablets for the purpose of intragastric floating drug delivery.
- Interpretation limits
- Verbatim excerpts from the authors’ abstract; the closing excerpt may describe a finding, limitation or recommendation. Design, population, effect size and uncertainty have not been independently extracted or appraised. Read the complete abstract and linked paper before interpreting the findings.
Read complete abstract (197 words)
The aim of this study was to explore the feasibility of fused deposition modeling (FDM) 3D printing to prepare intragastric floating sustained release (FSR) tablets. Domperidone (DOM), an insoluble weak base, was chosen as a model drug to investigate the potential of FSR in increasing its oral bioavailability and reducing its administration frequency. DOM was successfully loaded into hydroxypropyl cellulose (HPC) filaments using hot melt extrusion (HME). The filaments were then printed into hollow structured tablets through changing the shell numbers and the infill percentages. Physical characterization results indicated that the majority of DOM gradually turned into the amorphous form during the fabrication process. The optimized formulation (contain 10% DOM, with 2 shells and 0% infill) exhibited the sustained release characteristic and was able to float for about 10 h in vitro. Radiographic images showed that the BaSO4-labeled tablets were retained in the stomach of rabbits for more than 8 h. Furthermore, pharmacokinetic studies showed the relative bioavailability of the FSR tablets compared with reference commercial tablets was 222.49 ± 62.85%. All the results showed that FDM based 3D printing might be a promising way to fabricate hollow tablets for the purpose of intragastric floating drug delivery.
Abstract reproduced from the open-access article under the recorded cc by licence; © the authors. PMID 28588251 · DOI · PMC5460192
What Evidence Do We Have for Pharmaceutical Galactagogues in the Treatment of Lactation Insufficiency?-A Narrative Review [2]
Abstract reading summary — source excerpts
- Opening excerpt
- Inadequate breast milk supply is a frequently reported reason for early discontinuation of breastfeeding and represents a critical opportunity for intervening to improve breastfeeding outcomes.
- Closing excerpt
- The review provides an overview of key evidence gaps and areas of future research, including the impacts of pharmaceutical galactagogues on breast milk composition and understanding factors contributing to individual treatment response to pharmaceutical galactagogues.
- Interpretation limits
- Verbatim excerpts from the authors’ abstract; the closing excerpt may describe a finding, limitation or recommendation. Design, population, effect size and uncertainty have not been independently extracted or appraised. Read the complete abstract and linked paper before interpreting the findings.
Read complete abstract (211 words)
Inadequate breast milk supply is a frequently reported reason for early discontinuation of breastfeeding and represents a critical opportunity for intervening to improve breastfeeding outcomes. For women who continue to experience insufficient milk supply despite the utilisation of non-pharmacological lactation support strategies, pharmacological intervention with medications used to augment lactation, commonly referred to as galactagogues, is common. Galactagogues exert their pharmacological effects through altering the complex hormonal milieu regulating lactation, particularly prolactin and oxytocin. This narrative review provides an appraisal of the existing evidence regarding the efficacy and safety of pharmaceutical treatments for lactation insufficiency to guide their use in clinical practice. The greatest body of evidence surrounds the use of domperidone, with studies demonstrating moderate short-term improvements in breast milk supply. Evidence regarding the efficacy and safety of metoclopramide is less robust, but given that it shares the same mechanism of action as domperidone it may represent a potential treatment alternative where domperidone is unsuitable. Data on remaining interventions such as oxytocin, prolactin and metformin is too limited to support their use in clinical practice. The review provides an overview of key evidence gaps and areas of future research, including the impacts of pharmaceutical galactagogues on breast milk composition and understanding factors contributing to individual treatment response to pharmaceutical galactagogues.
Abstract reproduced from the open-access article under the recorded cc by licence; © the authors. PMID 31035376 · DOI · PMC6567188
Metoclopramide or domperidone improves post-pyloric placement of spiral nasojejunal tubes in critically ill patients: a prospective, multicenter, open-label, randomized, controlled clinical trial [3]
Abstract reading summary — source excerpts
- Opening excerpt
- IntroductionThe use of prokinetic agents on post-pyloric placement of spiral nasojejunal tubes is controversial.
- Closing excerpt
- Registered 21 February 2012.
- Interpretation limits
- Verbatim excerpts from the authors’ abstract; the closing excerpt may describe a finding, limitation or recommendation. Design, population, effect size and uncertainty have not been independently extracted or appraised. Read the complete abstract and linked paper before interpreting the findings.
Read complete abstract (238 words)
IntroductionThe use of prokinetic agents on post-pyloric placement of spiral nasojejunal tubes is controversial. The aim of the present study was to examine if metoclopramide or domperidone can increase the success rate of post-pyloric placement of spiral nasojejunal tubes.MethodsA multicenter, open-label, randomized, controlled trial was conducted in seven hospitals in China between April 2012 and February 2014. Patients admitted to the intensive care unit and requiring enteral nutrition for more than three days were randomly assigned to the metoclopramide, domperidone or control groups (1:1:1 ratio). The primary outcome was defined as the success rate of post-pyloric placement of spiral nasojejunal tubes, assessed 24 hours after initial placement. Secondary outcomes included success rate of post-D1, post-D2, post-D3 and proximal jejunum placement and tube migration distance. Safety of the study drugs and the tubes during the entire study period were recorded.ResultsIn total, 307 patients were allocated to the metoclopramide (n = 103), domperidone (n = 100) or control group (n = 104). The success rate of post-pyloric placement after 24 hours in the metoclopramide, domperidone and control groups was 55.0%, 51.5% and 27.3%, respectively (P = 0.0001). Logistic regression analysis identified the use of prokinetic agents, Acute Physiology and Chronic Health Evaluation (APACHE) II score ConclusionsProkinetic agents, such as metoclopramide or domperidone, are effective at improving the success rate of post-pyloric placement of spiral nasojejunal tubes in critically ill patients.Trial registrationChinese Clinical Trial Registry ChiCTR-TRC-12001956 . Registered 21 February 2012.
Abstract reproduced from the open-access article under the recorded cc by licence; © the authors. PMID 25880172 · DOI · PMC4367875
Unveiling advanced green assessment of simple and cost effective spectrophotometric determination of domperidone and pantoprazole for gastrointestinal disorders [4]
Abstract reading summary — source excerpts
- Opening excerpt
- In the pursuit of sustainable pharmaceutical analysis, Green Analytical Chemistry emerges as a vital approach to protect both human health and the environment.
- Closing excerpt
- These methods were rigorously assessed for their environmental sustainability using green analytical chemistry metrics: The Analytical Eco-Scale, the Modified Green Analytical Procedure Index (MoGAPI), the Analytical Green Star Area (AGSA), Carbon footprint (CaFRI), Blueness evaluation using BAGI tools, Click Analytical Chemistry Index (CACI) and the Multi-Color Assessment (MA) Tool.
- Interpretation limits
- Verbatim excerpts from the authors’ abstract; the closing excerpt may describe a finding, limitation or recommendation. Design, population, effect size and uncertainty have not been independently extracted or appraised. Read the complete abstract and linked paper before interpreting the findings.
Read complete abstract (219 words)
In the pursuit of sustainable pharmaceutical analysis, Green Analytical Chemistry emerges as a vital approach to protect both human health and the environment. This study focuses on a green analytical approach for the simultaneous evaluation of Domperidone (DP) and Pantoprazole (PP), two widely used gastrointestinal drugs with distinct mechanisms and therapeutic roles. A suite of advanced spectrophotometric techniques, including the Deconvoluted Fourier method (DF), the Dual Wavelength method (DW), and both First-Order Derivative (D1) and Second-Order Derivative (D2) methods, was developed for the simultaneous determination of DP and PP. The linearity ranges were found to be (1.0- 9.0) µg/mL for both drugs; this range applies to all the proposed methods. Accuracy and reliability were confirmed via the standard addition technique. Furthermore, the performance of the suggested approaches was statistically compared with that of previously reported HPLC methods, showing their efficiency, eco-friendliness, and practical applicability. The methods were applied to laboratory-prepared combinations with varying concentrations of the two drugs to evaluate selectivity, as well as to their commercially available dosage forms. These methods were rigorously assessed for their environmental sustainability using green analytical chemistry metrics: The Analytical Eco-Scale, the Modified Green Analytical Procedure Index (MoGAPI), the Analytical Green Star Area (AGSA), Carbon footprint (CaFRI), Blueness evaluation using BAGI tools, Click Analytical Chemistry Index (CACI) and the Multi-Color Assessment (MA) Tool.
Abstract reproduced from the open-access article under the recorded cc by licence; © the authors. PMID 41588077 · DOI · PMC12848105
Key reviews and meta-analyses
The most cited review-type papers among PubMed’s best-match results for this heading, listed with bibliographic details only. Follow the links for the full text and access terms.
- Research article Domperidone: review of pharmacology and clinical applications in gastroenterology [5]
- Research article Domperidone. A review of its pharmacological activity, pharmacokinetics and therapeutic efficacy in the symptomatic treatment of chronic dyspepsia and as an antiemetic [6]
- Research article Domperidone: a peripherally acting dopamine2-receptor antagonist [7]
- Research article Efficacy of cisapride and domperidone in functional (nonulcer) dyspepsia: a meta-analysis [8]
- Research article Galactogogues: medications that induce lactation [9]
- Research article A systematic review of the efficacy of domperidone for the treatment of diabetic gastroparesis [10]
References
- Chai X, Chai H, Wang X, Yang J, Li J, Zhao Y, et al.. Fused Deposition Modeling (FDM) 3D Printed Tablets for Intragastric Floating Delivery of Domperidone. . 2017. PMID 28588251 · DOI · PMC5460192
- Grzeskowiak LE, Wlodek ME, Geddes DT. What Evidence Do We Have for Pharmaceutical Galactagogues in the Treatment of Lactation Insufficiency?-A Narrative Review. . 2019. PMID 31035376 · DOI · PMC6567188
- Hu B, Ye H, Sun C, Zhang Y, Lao Z, Wu F, et al.. Metoclopramide or domperidone improves post-pyloric placement of spiral nasojejunal tubes in critically ill patients: a prospective, multicenter, open-label, randomized, controlled clinical trial. . 2015. PMID 25880172 · DOI · PMC4367875
- Darweish E, El-Henawee MM, Labib MAE, Kabil NAS. Unveiling advanced green assessment of simple and cost effective spectrophotometric determination of domperidone and pantoprazole for gastrointestinal disorders. . 2026. PMID 41588077 · DOI · PMC12848105
- Reddymasu SC, Soykan I, McCallum RW. Domperidone: review of pharmacology and clinical applications in gastroenterology. Am J Gastroenterol. 2007. PMID 17488253 · DOI
- Brogden RN, Carmine AA, Heel RC, Speight TM, Avery GS. Domperidone. A review of its pharmacological activity, pharmacokinetics and therapeutic efficacy in the symptomatic treatment of chronic dyspepsia and as an antiemetic. Drugs. 1982. PMID 6756878 · DOI
- Barone JA. Domperidone: a peripherally acting dopamine2-receptor antagonist. Ann Pharmacother. 1999. PMID 10332535 · DOI
- Veldhuyzen van Zanten SJ, Jones MJ, Verlinden M, Talley NJ. Efficacy of cisapride and domperidone in functional (nonulcer) dyspepsia: a meta-analysis. Am J Gastroenterol. 2001. PMID 11280535 · DOI
- Gabay MP. Galactogogues: medications that induce lactation. J Hum Lact. 2002. PMID 12192964 · DOI
- Sugumar A, Singh A, Pasricha PJ. A systematic review of the efficacy of domperidone for the treatment of diabetic gastroparesis. Clin Gastroenterol Hepatol. 2008. PMID 18524689 · DOI
About this article
- Sources
- NLM Medical Subject Headings (definition, synonyms); NCBI PubMed (counts, identifiers); Europe PMC (open-access abstracts and citation counts).
- Verification
- Every reference was resolved against PubMed on 2026-10-31; title, year and DOI matched.
- Review state
- automated source verified; no human expert review has been recorded yet.
- Version
- 1, last updated 2026-10-31.
See how EvidenceLib is built. Spotted an error? Email support@evidencehelix.com.
Evidence strength
EvidenceHelix's computed view of the study designs behind this topic: how common meta-analyses, randomized trials and reviews are, how recent the literature is, and a plain-language reading. It describes the design mix of the literature. It is not a quality appraisal of any study, and it is not medical advice.